Could the next gene ther­a­py man­u­fac­tur­ing hub be Cincin­nati? A $100M bet says yes

4 years ago
Cell/Gene Tx
Manufacturing

No­var­tis en­lists Mol­e­c­u­lar Part­ners on ra­di­oli­gand ther­a­py dis­cov­ery; Galera blames CRO er­ror for PhI­II fail­ure — ...

4 years ago
News Briefing

Mesoblast shares tank af­ter No­var­tis aban­dons a part­ner­ship for the biotech's po­ten­tial Covid-19 treat­ment

4 years ago
Deals
Coronavirus

As dust set­tles on the Are­na buy­out, Pfiz­er ex­ec sug­gests com­pa­ny will pur­sue a more ag­gres­sive M&A strat­e­gy

4 years ago
Deals
Pharma

Mod­er­na plots mR­NA vac­cine fac­to­ry in Aus­tralia that can churn out 100M dos­es per year

4 years ago
Manufacturing

Ef­fi­ca­cy of Pfiz­er's Covid pill holds up in fi­nal analy­sis, re­duc­ing risk of hos­pi­tal­iza­tion or death by al­most 90%

4 years ago
Coronavirus

ASH: Roche's an­ti­body-drug con­ju­gate Po­livy added to chemo-an­ti­body com­bo boosts sur­vival in ear­ly-stage lym­phoma

4 years ago
R&D

ASH: Sanofi un­corks late-stage da­ta for RNAi drug fi­tusir­an in he­mo­phil­ia, with all eyes on safe­ty pro­file

4 years ago
R&D
Cell/Gene Tx

Ada­gio raised $750M+ for an an­ti­body against fu­ture vari­ants. It failed against Omi­cron

4 years ago
Coronavirus

Lin­ing up a fil­ing for lead ROS1 in­hibitor, transpa­cif­ic on­col­o­gy biotech An­Heart Ther­a­peu­tics rais­es $61M

4 years ago
Financing
China

Covid-19 roundup: Study sug­gests Omi­cron vari­ant could es­cape pro­tec­tion of Pfiz­er/BioN­Tech vac­cine; Serum In­sti­tute ...

4 years ago
Coronavirus

Sen­ate fi­nance chair to HHS: Wait on Bio­gen's Aduhelm NCD pri­or to en­forc­ing his­tor­i­cal­ly steep Medicare pre­mi­um ...

4 years ago
Pharma

Bris­tol My­ers antes up on a $920M part­ner­ship play for a next-gen — but ear­ly stage — bis­pe­cif­ic with a cou­ple of ...

4 years ago
Deals
Cell/Gene Tx

Q&A: Sanofi's Raj Ver­ma talks con­nec­tions and pan­dem­ic shifts amid new strat­e­gy di­rec­tion

4 years ago
Pharma
Marketing

M&A sea­son starts ear­ly? CSL seals $11.7B ac­qui­si­tion of Vi­for Phar­ma

4 years ago
Deals

ASH: With PhI­II da­ta in hand, Atara eyes a sub­mis­sion to treat a small but des­per­ate group of trans­plant pa­tients

4 years ago
R&D
Cell/Gene Tx

ASH: Af­ter a pi­lot study of­fers a glimpse of hope for Tes­sa's CD30-tar­get­ing CAR-T, ex­ecs sprint to­ward a piv­otal ...

4 years ago
R&D
Cell/Gene Tx

Aim cam­era for more in­fo? QR codes' pop­u­lar­i­ty por­tends po­ten­tial phar­ma pro­mos

4 years ago
Pharma
Marketing

ASH: No­var­tis rolls out ear­ly da­ta for a pair of 'sec­ond-gen' CAR-Ts with more pro­duc­tive cells de­liv­ered faster

4 years ago
R&D
Cell/Gene Tx

ASH: Gilead­'s CAR-T Yescar­ta holds up in more first-line lym­phoma pa­tients as part of ear­li­er use push

4 years ago
R&D
Cell/Gene Tx

In­tel­lia dos­es first pa­tient with an­ti-HAE gene ther­a­py; So­bi an­nounces new R&D chief

4 years ago
News Briefing

Sooth­ing na­ture sounds on Ab­b­Vie's mi­graine drug Tik­Tok of­fer a break from in­fi­nite scrolling

4 years ago
Pharma
Marketing

Biotech short sell­er lands on fed­s' watch list amid sweep­ing probe — re­port

4 years ago
People

Bel­lus soars on pos­i­tive mid-stage read­out for its Mer­ck cough ri­val, de­spite a fail­ure in atopic der­mati­tis

4 years ago
R&D
First page Previous page 601602603604605606607 Next page Last page
A service from the Financial Times